Literature DB >> 21609016

Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions.

Landon R Whitby1, Yoshio Ando, Vincent Setola, Peter K Vogt, Bryan L Roth, Dale L Boger.   

Abstract

The design and synthesis of a β-turn mimetic library as a key component of a small-molecule library targeting the major recognition motifs involved in protein-protein interactions is described. Analysis of a geometric characterization of 10,245 β-turns in the protein data bank (PDB) suggested that trans-pyrrolidine-3,4-dicarboxamide could serve as an effective and synthetically accessible library template. This was confirmed by initially screening select compounds against a series of peptide-activated GPCRs that recognize a β-turn structure in their endogenous ligands. This validation study was highlighted by identification of both nonbasic and basic small molecules with high affinities (K(i) = 390 and 23 nM, respectively) for the κ-opioid receptor (KOR). Consistent with the screening capabilities of collaborators and following the design validation, the complete library was assembled as 210 mixtures of 20 compounds, providing a total of 4200 compounds designed to mimic all possible permutations of 3 of the 4 residues in a naturally occurring β-turn. Unique to the design and because of the C(2) symmetry of the template, a typical 20 × 20 × 20-mix (8000 compounds prepared as 400 mixtures of 20 compounds) needed to represent 20 variations in the side chains of three amino acid residues reduces to a 210 × 20-mix, thereby simplifying the library synthesis and subsequent screening. The library was prepared using a solution-phase synthetic protocol with liquid-liquid or liquid-solid extractions for purification and conducted on a scale that insures its long-term availability for screening campaigns. Screening the library against the human opioid receptors (KOR, MOR, and DOR) identified not only the activity of library members expected to mimic the opioid receptor peptide ligands but also additional side-chain combinations that provided enhanced receptor binding selectivities (>100-fold) and affinities (as low as K(i) = 80 nM for KOR). A key insight to emerge from the studies is that the phenol of Tyr in endogenous ligands bearing the H-Tyr-Pro-Trp/Phe-Phe-NH(2) β-turn is important for MOR binding but may not be important for KOR (accommodated, but not preferred) and that the resulting selectivity for KOR observed with its removal can be increased by replacing the phenol OH with a chlorine substituent, further enhancing KOR affinity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609016      PMCID: PMC3134394          DOI: 10.1021/ja201878v

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  99 in total

1.  Solution-phase parallel synthesis of a pharmacophore library of HUN-7293 analogues: a general chemical mutagenesis approach to defining structure-function properties of naturally occurring cyclic (depsi)peptides.

Authors:  Yan Chen; Melitta Bilban; Carolyn A Foster; Dale L Boger
Journal:  J Am Chem Soc       Date:  2002-05-15       Impact factor: 15.419

Review 2.  Recent advances in selective opioid receptor agonists and antagonists.

Authors:  Masakatsu Eguchi
Journal:  Med Res Rev       Date:  2004-03       Impact factor: 12.944

Review 3.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

Review 4.  Update 1 of: Beta-strand mimetics.

Authors:  Wendy A Loughlin; Joel D A Tyndall; Matthew P Glenn; Timothy A Hill; David P Fairlie
Journal:  Chem Rev       Date:  2010-04-12       Impact factor: 60.622

5.  Aromatic-aromatic and proline-aromatic interactions in endomorphin-1 and endomorphin-2.

Authors:  Balázs Leitgeb; Géza Tóth
Journal:  Eur J Med Chem       Date:  2005-03-24       Impact factor: 6.514

Review 6.  The endomorphin system and its evolving neurophysiological role.

Authors:  Jakub Fichna; Anna Janecka; Jean Costentin; Jean-Claude Do Rego
Journal:  Pharmacol Rev       Date:  2007-03       Impact factor: 25.468

Review 7.  Scaffolds for blocking protein-protein interactions.

Authors:  Stefan J Hershberger; Song-Gil Lee; Jean Chmielewski
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

8.  Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction.

Authors:  Jeffrey P Plante; Thomas Burnley; Barbora Malkova; Michael E Webb; Stuart L Warriner; Thomas A Edwards; Andrew J Wilson
Journal:  Chem Commun (Camb)       Date:  2009-06-24       Impact factor: 6.222

9.  CSI-FID: high throughput label-free detection of DNA binding molecules.

Authors:  Karl E Hauschild; James S Stover; Dale L Boger; Aseem Z Ansari
Journal:  Bioorg Med Chem Lett       Date:  2009-05-03       Impact factor: 2.823

10.  Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation.

Authors:  Jin Shi; James S Stover; Landon R Whitby; Peter K Vogt; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2009-09-17       Impact factor: 2.823

View more
  22 in total

1.  Design of RNA-targeting macrocyclic peptides.

Authors:  Matthew J Walker; Gabriele Varani
Journal:  Methods Enzymol       Date:  2019-06-13       Impact factor: 1.600

2.  Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic library.

Authors:  Landon R Whitby; Kristopher E Boyle; Lifeng Cai; Xiaoqian Yu; Miriam Gochin; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2012-03-03       Impact factor: 2.823

3.  Inhibition of adenovirus replication by a trisubstituted piperazin-2-one derivative.

Authors:  Javier Sanchez-Cespedes; Crystal L Moyer; Landon R Whitby; Dale L Boger; Glen R Nemerow
Journal:  Antiviral Res       Date:  2014-06-04       Impact factor: 5.970

4.  Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Lijing Su; Murali M R P Surakattula; Michael Berger; Hua Huang; Elliot K Beutler; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2016-04-25       Impact factor: 7.446

Review 5.  Peptidomimetic therapeutics: scientific approaches and opportunities.

Authors:  Nir Qvit; Samuel J S Rubin; Travis J Urban; Daria Mochly-Rosen; Eric R Gross
Journal:  Drug Discov Today       Date:  2016-11-14       Impact factor: 7.851

6.  Extension of the CHARMM General Force Field to sulfonyl-containing compounds and its utility in biomolecular simulations.

Authors:  Wenbo Yu; Xibing He; Kenno Vanommeslaeghe; Alexander D MacKerell
Journal:  J Comput Chem       Date:  2012-07-23       Impact factor: 3.376

7.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

Review 8.  Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

Authors:  Lu Lu; Fei Yu; Lifeng Cai; Asim K Debnath; Shibo Jiang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

9.  Discovery libraries targeting the major enzyme classes: the serine hydrolases.

Authors:  Katerina Otrubova; Venkat Srinivasan; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2014-06-27       Impact factor: 2.823

10.  Ligand-Enabled γ-C(sp(3))-H Olefination of Amines: En Route to Pyrrolidines.

Authors:  Heng Jiang; Jian He; Tao Liu; Jin-Quan Yu
Journal:  J Am Chem Soc       Date:  2016-02-04       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.